Company Statement: Gilead Sciences to Acquire Calistoga Pharmaceuticals for $375 Million
MLex Summary: Gilead Sciences seeks to acquire Calistoga Pharmaceuticals, a biotechnology company from Seattle focused on the development of medicines that treat cancer and inflammatory diseases. Companies anticipate the deal will...To view the full article, register now.
Already a subscriber? Click here to view full article